Form 4: Abbott Laboratories Director Equity Grant Disclosure

Director Nancy McKinstry received a grant of restricted stock units and stock options as part of the 2026 Incentive Stock Program.

Summary

• Director Nancy McKinstry was granted 2,286 restricted stock units (RSUs) on April 24, 2026.
• The director also received a grant of 2,305 stock options with an exercise price of $91.86.
• The RSUs will be settled in common shares upon separation from service, death, or a change in control.
• The stock options are exercisable immediately and expire on April 23, 2036.
• Following these transactions, the director's total beneficial ownership of common shares is 41,010.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that carries no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized incentive structure under the 2026 Incentive Stock Program.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• Market volatility affecting the value of equity-based compensation.
• Regulatory and compliance risks associated with Section 16 reporting requirements.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director equity compensation.

Management Comments

• The awards were granted under the Abbott Laboratories 2026 Incentive Stock Program.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for director compensation within the large-cap healthcare and medical device sector, reflecting typical corporate governance practices for executive and board retention.

Comparison to Industry Standards

• The use of RSUs and stock options for board compensation is consistent with industry standards for S&P 500 companies.
• The vesting and settlement terms align with common practices for director equity programs in the pharmaceutical and medical technology industries.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; reflects standard board compensation practices.

Next Steps

• Future reporting of any changes in beneficial ownership as required by Section 16(a).

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Director Compensation, Equity Grant, Insider Trading, Stock Options, Restricted Stock Units